The Pro Medicus Ltd (ASX: PME) share price is in focus today after the company secured a five-year, $37 million contract renewal with Northwestern Medicine, featuring increased minimum spend and higher fees per transaction.
Image source: Getty Images
What did Pro Medicus report?
- Signed a 5-year, $37 million contract renewal with Northwestern Medicine
- The renewal is based on transaction volume, with potential upside
- Increased minimum commitments and higher fee per exam locked in
- Nearly $80 million in contract renewals agreed in the past month
What else do investors need to know?
The renewed agreement is with Northwestern Medicine, a leading academic health system in Chicago, serving over 200 sites. The contract not only increases the minimum transaction volume but also raises the fee paid to Pro Medicus for each exam, reflecting growth since the initial agreement.
This contract builds on Pro Medicus's strong client retention track record. The company's Visage 7 Viewer platform is now firmly established within Northwestern Medicine, supporting both financial and clinical outcomes.
What did Pro Medicus management say?
Chief Executive Officer Dr Sam Hupert said:
We are extremely pleased that in addition to committing to a second five-year term at an increased fee per exam, NM have also committed to an increase in their minimums reflecting the growth in their exam volumes since standardising on our platform five years ago.
What's next for Pro Medicus?
Pro Medicus continues to invest in its core imaging platform and grow its base of recurring contract revenue. Management highlighted almost $80 million in recent renewals, supporting the company's belief in the lasting value of its technology.
The group plans to maintain its focus on client retention and further expansion in international markets, as well as ongoing innovation within its medical imaging software suite.
Pro Medicus share price snapshot
Over the past 12 months, Pro Medicus shares have declined 40%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.
